Less may be more in postop colorectal cancer follow-up
June 27, 2013|Hematology and Oncology
Author and Disclosure Information
AT ASCO ANNUAL MEETING 2013
Dr. Maughan said the disparity between the current meta-analysis and the Cochrane review may be because the latter included six studies, not three, and that the survival data from FACS may not be fully mature. A further analysis of the FACS data is planned in about 18 months.
Dr. Mant and his coauthors reported having no financial disclosures.
Mant, D., et al. "Effect of 3-5 years of scheduled CED and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial." Ab. 3500.
